NCT02856152View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Participants

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Healthy Volunteer
Interventions
DRUG

GDC-0276 capsule

Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.

DRUG

GDC-0276 tablets

Three 90 mg GDC-0276 tablets administered orally.

Trial Locations (1)

NG11 6JS

Quotient Clinical Ltd, Clinical Research Unit, Nottingham

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY